ATE299179T1 - Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung - Google Patents

Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung

Info

Publication number
ATE299179T1
ATE299179T1 AT99902219T AT99902219T ATE299179T1 AT E299179 T1 ATE299179 T1 AT E299179T1 AT 99902219 T AT99902219 T AT 99902219T AT 99902219 T AT99902219 T AT 99902219T AT E299179 T1 ATE299179 T1 AT E299179T1
Authority
AT
Austria
Prior art keywords
suppressor trna
oligonucleotides
methods
human suppressor
human
Prior art date
Application number
AT99902219T
Other languages
English (en)
Inventor
Rekha G Panchal
Charles J Link Jr
Original Assignee
Human Gene Therapy Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Gene Therapy Res Inst filed Critical Human Gene Therapy Res Inst
Application granted granted Critical
Publication of ATE299179T1 publication Critical patent/ATE299179T1/de

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B10/00—Transmission systems employing electromagnetic waves other than radio-waves, e.g. infrared, visible or ultraviolet light, or employing corpuscular radiation, e.g. quantum communication
    • H04B10/25—Arrangements specific to fibre transmission
    • H04B10/2589—Bidirectional transmission
    • H04B10/25891—Transmission components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Electromagnetism (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT99902219T 1998-01-14 1999-01-13 Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung ATE299179T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7141698P 1998-01-14 1998-01-14
PCT/US1999/000717 WO1999036519A1 (en) 1998-01-14 1999-01-13 HUMAN SUPPRESSOR tRNA OLIGONUCLEOTIDES AND METHODS OF USE FOR SAME

Publications (1)

Publication Number Publication Date
ATE299179T1 true ATE299179T1 (de) 2005-07-15

Family

ID=22101183

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902219T ATE299179T1 (de) 1998-01-14 1999-01-13 Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung

Country Status (8)

Country Link
US (2) US6309830B1 (de)
EP (1) EP1045902B1 (de)
JP (1) JP2002508959A (de)
AT (1) ATE299179T1 (de)
AU (1) AU2225199A (de)
CA (1) CA2318374C (de)
DE (1) DE69926052T2 (de)
WO (1) WO1999036519A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508959A (ja) * 1998-01-14 2002-03-26 ヒューマン ジーン セラピー リサーチ インスティテュート ヒトのサプレッサーｔＲＮＡオリゴヌクレオチド、及びそれを用いる方法
KR20010079671A (ko) * 1998-08-20 2001-08-22 스티븐 에이. 서윈. 엠.디. 재조합 유전자 생성물을 생성시키는 동안 세포독성을조절하는 억제 ｔＲＮＡ의 용도
WO2003033521A1 (en) * 2001-10-16 2003-04-24 Massachusetts Institute Of Technology Inppressor trna system in mammalian cells for the introduction of unnatural amino acids in polypeptides.
US20050261210A1 (en) * 2004-02-19 2005-11-24 Bhatnagar Rajiv S Nonsense suppressor agents in treatment of cutaneous and gastrointestinal disorders
WO2005086768A2 (en) * 2004-03-11 2005-09-22 Albert Einstein College Of Medicine Of Yeshiva University Enhanced production of functional proteins from defective genes
WO2008064304A2 (en) * 2006-11-22 2008-05-29 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
ATE553764T1 (de) * 2007-09-14 2012-05-15 Trana Discovery Zusammensetzungen und verfahren zur identifizierung von inhibitoren einer retrovirusinfektion
CA2776044A1 (en) * 2008-09-29 2010-04-01 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
CN107177592B (zh) * 2016-03-10 2021-03-30 北京大学 抑制性tRNA通读提前终止密码子疾病中的截短蛋白
CN110612353A (zh) * 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
MX2020004587A (es) * 2017-11-02 2021-04-12 Univ Iowa Res Found Métodos de rescate de codones de paro mediante reasignación genética con ace-arnt.
WO2020069194A1 (en) * 2018-09-26 2020-04-02 Case Western Reserve University Methods and compositions for treating a premature stop codon-mediated disorder
JP2022528696A (ja) * 2019-04-11 2022-06-15 アークタラス テラピュウティクス、インク アンチコドンループを延長した合成転移ｒｎａ
LU101182B1 (en) * 2019-04-11 2020-10-12 Univ Hamburg Synthetic transfer RNA with extended anticodon loop
JP7712270B2 (ja) 2019-11-01 2025-07-23 テバード バイオサイエンシズ インコーポレイテッド 未成熟終止コドン媒介障害を処置するための方法および組成物
US11827880B2 (en) 2019-12-02 2023-11-28 Shape Therapeutics Inc. Therapeutic editing
BR112022020780A2 (pt) 2020-04-14 2022-11-29 Flagship Pioneering Innovations Vi Llc Composições de trem e usos das mesmas
US20230203510A1 (en) * 2020-05-29 2023-06-29 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
WO2022125531A1 (en) * 2020-12-07 2022-06-16 President And Fellows Of Harvard College Methods for making and using genomically recoded cells
AU2023212951A1 (en) * 2022-01-25 2024-08-29 Hc Bioscience, Inc. Universal suppressor trnas and uses thereof
USD1118947S1 (en) * 2024-05-29 2026-03-17 Shock Doctor, Inc. Knee brace
USD1121161S1 (en) * 2024-05-29 2026-03-31 Shock Doctor, Inc. Knee brace

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687737A (en) 1982-11-12 1987-08-18 Massachusetts Institute Of Technology Mammalian suppressor genes
US4970155A (en) * 1983-03-07 1990-11-13 Abbott Laboratories HSV helper virus independent vector
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
JP2002508959A (ja) * 1998-01-14 2002-03-26 ヒューマン ジーン セラピー リサーチ インスティテュート ヒトのサプレッサーｔＲＮＡオリゴヌクレオチド、及びそれを用いる方法

Also Published As

Publication number Publication date
CA2318374A1 (en) 1999-07-22
US7029665B2 (en) 2006-04-18
DE69926052T2 (de) 2006-04-27
EP1045902A1 (de) 2000-10-25
US20020156042A1 (en) 2002-10-24
CA2318374C (en) 2012-09-04
JP2002508959A (ja) 2002-03-26
DE69926052D1 (de) 2005-08-11
WO1999036519A1 (en) 1999-07-22
EP1045902B1 (de) 2005-07-06
AU2225199A (en) 1999-08-02
US6309830B1 (en) 2001-10-30
HK1033955A1 (en) 2001-10-05

Similar Documents

Publication Publication Date Title
DE69926052D1 (de) Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung
DE59914996D1 (en) Heterocyclisch substituierte amide als calpainhemmer
DE60044058D1 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
EP1423537A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung von morbus huntington
DE69525736D1 (de) Oligonukleotid und kanzerostatisches mittel das dieses als aktiven inhaltstoff enthält
EP2444809A3 (de) Verfahren zur Herstellung und zum Screening von Proteasen mit veränderter Spezifizität
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
DE60023870T2 (de) Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
NO973838D0 (no) DNA-molekyler, deres fremstilling samt anvendelse ved genterapi
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
ZA984463B (en) Fused dihydropyrans
PT1246835E (pt) Sapogeninas substituídas e sua utilização
DE60044247D1 (de) Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
DE69837267D1 (de) Kcnq kaliumkanäle und verfahren zur deren modulierung
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
TR200200278T2 (tr) Kalsilitik bileşimler
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
AU4037299A (en) Genetically-modified fibroblasts and the use thereof
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
BRPI0408077A (pt) composições e métodos para prevenção e tratamento de doenças relacionadas com endotoxina e condições
FR2749857B1 (fr) Generation de molecules replicatives in vivo
EP0762887A4 (de) Acylierte enolderivate als vorläufdrogen von elastaseinhibitoren
AU2002316158A1 (en) Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties